Delta4, founded in 2019, is an AI Drug Discovery TechBio company at the forefront of detecting relationships between drugs with a known safety profile and rare diseases. This allows us to unearth new indications that could potentially revolutionize the way treatments find their way to patients. With a dedicated team of professionals, ranging from computational biologists to intellectual property experts, Delta4 is driven by the singular mission of enhancing patient care across the globe.
By harnessing the power of our unique AI-powered platform, Hyper-C, Delta4 has been at the spearhead of drug repurposing and indication expansion. Our main goal is to pinpoint undetected correlations between existing drugs and diseases. Through this, we present new therapeutic options more swiftly, economically, and efficiently than ever before.
Operated by our highly skilled team of computational biologists, Hyper-C is our keystone in identifying these relationships. It’s not just about speed but the precision and accuracy with which we offer unique insights for drug repurposing and indication expansion.
Drug repurposing and indication expansion represent a paradigm shift, offering a cost-effective way to discover new uses for existing drugs. Our investment in Hyper-C is a testament to our commitment to revolutionizing the drug discovery space.
Kurt Herpel (CEO) is a pharma executive with vast experience in leading organizations. Besides big pharma, he is experienced in start-up situations and smaller enterprises.
Klaus Kratochwill (CSO) is a translational researcher, and biochemist by training. He is an expert in omics data generation and analysis. In Delta4, he is responsible for coordinating all scientific activities.
Alfred Steininger (CFO) is a financial professional with a deep knowledge of banking and capital markets. He has worked in a couple of different countries and for both large and small organizations.
Kurt Herpel, CEO
Klaus Kratochwill, CSO
Alfred Steininger, CFO
For media inquiries, partnership opportunities, or more information:
Thank you for your interest in Delta4. We are driven by innovation and the ambition to pave a brighter path in healthcare, transforming lives worldwide.